What is known and objectives: Different population pharmacokinetics (PPK) models of tacrolimus have been established in various populations. However, the tacrolimus PPK model in paediatric systemic lupus erythematosus (PSLE) is still undefined. This study aimed to establish the tacrolimus PPK model in Chinese PSLE. 
| WHAT IS K NOWN AND OBJEC TIVE S
Systemic lupus erythematosus (SLE) is a chronic systemic autoimmune disease characterized by the production of a large number of autoantibodies in the blood. [1] [2] [3] [4] Whereas corticosteroids and immunosuppressants are widely used for treatment, cases of resistance have been reported and new treatments are sought in the clinical setting. 5 Tacrolimus is a medication that induces an immunosuppressive effect, and in recent years, it has been widely used in the treatment of SLE. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] However, tacrolimus has a narrow therapeutic window and displays considerable interindividual and intra-individual variabilities in its pharmacokinetics, with poor correlation between drug dosage and blood concentrations, making it difficult to define an optimal dose schedule. 16, 17 With population pharmacokinetics (PPK), pharmacokinetic information can be acquired from sparse data pooled in a large group of subjects. Moreover, the population analysis methodology differentiates between interindividual variability and residual unexplained variability. Hence, this method has greater statistical power to identify the effect of multiple factors on the pharmacokinetics of tacrolimus compared to traditional pharmacokinetic analysis and makes possible optimal dose scheduling. 18 Currently, different tacrolimus PPK models have been set up for various populations including renal transplant patients, [19] [20] [21] [22] [23] [24] liver transplant patients, [25] [26] [27] [28] [29] [30] haematopoietic stem cell transplant patients 31 and lung transplant patients. 32 However, the tacrolimus PPK model in patients with paediatric systemic lupus erythematosus (PSLE) is still unclear. This study aimed to investigate the PPK of tacrolimus in PSLE, and to identify factors that explain pharmacokinetic variability to facilitate individualized therapy.
| ME THODS

| Patients and data collection
Patients younger than 18 years of age who were diagnosed with SLE and on treatment with tacrolimus as therapy were chosen for our study. Patients were excluded if they had other serious diseases. 
| Drug administration
All patients were given oral tacrolimus. The initial dosage of tac- 
| Analytical method
Whole-blood concentrations of tacrolimus were measured by One-compartment model with first-order elimination was used to describe the absorption phase because all the tacrolimus concentrations in this research were trough concentrations. The bioavailability (F) and absorption with a lag time could not be estimated because tacrolimus was administered orally and its concentration data were insufficient. Hence, the PK parameters were comprised of apparent oral clearance (CL/F) and apparent volume of distribution (V/F).
| Population pharmacokinetic modelling
The absorption rate constant (Ka) of the model was fixed to 4.48 h
through literature study.
28,33,34
| Random-effect model
The interindividual variability in the PK parameters was explored using additive, proportional and exponential error models. The residual error variability was evaluated with the additive, proportional, exponential and mixed error models.
TA B L E 1 Demographic data of patients
| Covariate model
To explain the variability on PK parameters, the correlations between covariates were investigated and all the PK parameters esti- 
| Model validation
An internal bootstrap validation method was applied to evaluate the stability and reliability of the final parameter estimates. Bootstrap was generated by repeated random sampling with replacement from the original data. This procedure was performed with the software package Wings for NONMEM and repeated 1000 times with different random draws. The medians and 2.5%-97.5% percentiles of the bootstrap parameter estimates were compared with the final PK parameter estimates. The distribution of weighted residuals for the final model was evaluated by histogram and QQ figures.
The predictive performance of the final model was also evaluated by a prediction-corrected visual predictive check (VPC).
| RE SULTS
| Data collection
Nineteen Chinese patients with PSLE (6 boys and 13 girls) were available for the population modelling. The patients' characteristics and drug combinations are summarized in Tables 1 and 2 .
| Modelling
A one-compartment model with first-order absorption and elimina- 
TA B L E 2 Drug combination
CL/F and V/F, were estimated by NONMEM. Interindividual variability and residual variability were best described by exponential and proportional error models, respectively. All covariates were analysed in this study, and only the following covariates showed statistical significance on the PK parameters: methylprednisolone and simvastatin on CL/F, and duration of treatment with tacrolimus on V/F.
The changes in the OFV are shown in Table 3 
| Validation
The goodness-of-fit plots of the final model ( Figure 1 
| D ISCUSS I ON
Ka (h −1 ) 4.48 (fixed) - - - - θ
TA B L E 4 Parameter estimates of the final model and bootstrap validation
However, as tacrolimus displays considerable interindividual and intra-individual variabilities in its pharmacokinetics, the study of tacrolimus PPK is important. To our knowledge, our model is the first paediatric study of the PPK of tacrolimus in patients with SLE.
In the present study, a tacrolimus PPK was performed in Chinese patients with PSLE by a population modelling approach, which was especially suitable as ethical and logistical restrictions involved in studying paediatric patients prohibit excessive blood sampling, compared with traditional pharmacokinetic studies. It is common knowledge that tacrolimus is primarily metabolized in the liver and intestine by the oxidative enzyme CYP 3A subfamily, including CYP3A4 and the highly polymorphic CYP3A5. 41 Polymorphisms in CYP3A might associate with interindividual variations in tacrolimus dose determination. However, this possible pharmacogenomic effect has not been verified in clinical use in patients with PSLE.
In brief, the clinical efficacy and adverse effects are closely related to the blood concentration of tacrolimus.
| WHAT IS NE W AND CON CLUS I ON
We present the first PPK model of tacrolimus in patients with PSLE using data from routine monitoring in this real-world study. 
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